Acrivon Therapeutics, Inc. (ACRV)

In October 2025, Acrivon Therapeutics reported its Third Quarter 2025 Financial Results and Business Highlights, including the advancement of ACR-368 and preparation for initial clinical data disclosure for ACR-2316. In December 2025 - January 2026, Acrivon announced a clinical update on its ongoing Phase 2b studies and planned confirmatory Phase 3 trial for ACR-368, initial clinical data on ACR-2316, and other AP3 pipeline updates. In February 2026, Acrivon Therapeutics strengthened its precision medicine therapeutics capabilities with the launch of an internal CLIA-certified laboratory and presented at the TD Cowen 46th Annual Health Care Conference. In March 2026, Acrivon Therapeutics reported Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights and presented preclinical AP3 data at the 2026 AACR Annual Meeting. In April 2026, Acrivon highlighted preclinical data with three posters at AACR and announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). In May 2026, Acrivon Therapeutics is estimated to release its Q1 2026 earnings around May 13th, 2026.

As a clinical-stage biopharmaceutical company, Acrivon Therapeutics, Inc. does not currently have commercialized products generating revenue from sales. The concept of demand seasonality for its products and services is not applicable. The company's value and progress are tied to clinical trial outcomes, regulatory milestones, and pipeline advancements rather than seasonal consumer purchasing patterns.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology medicines. The company operates within the Professional, Scientific, and Technical Services sector and the Research and Development in Biotechnology industry. Acrivon utilizes its proprietary Generative Phosphoproteomics AP3 platform to identify patients whose tumors are predicted to be sensitive to specific treatments, enabling the creation of drug-specific OncoSignature companion diagnostics. Its major product candidates include ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2, ACR-2316, a novel, potent, selective dual WEE1 and PKMYT1 inhibitor small molecule candidate, and ACR-6840, an internally discovered development candidate targeting CDK11.

Acrivon Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States. The company also has a global team operating out of Medicon Valley in Southern Scandinavia, indicating a presence in two leading life science clusters.

Acrivon Therapeutics maintains a reputation as a clinical-stage biopharmaceutical company committed to developing precision oncology medicines through its innovative AP3 platform. Events that have positively affected its reputation include receiving FDA Fast Track designation for ACR-368 monotherapy and Breakthrough Device designation for the ACR-368 OncoSignature assay in endometrial cancer, reporting maturing data from the ACR-368 study showing a confirmed overall response rate (cORR) of 52% in serous endometrial cancer, presenting preclinical data at major conferences like AACR, and launching an internal CLIA-certified laboratory to strengthen precision medicine capabilities. No significant negative events impacting Acrivon Therapeutics' brand reputation were found in the past year.

Acrivon Therapeutics, Inc. stock ownership is a mix of institutional investors, insiders, and retail investors. Approximately 28.47% to 32.65% of the company's stock is held by institutional investors, insiders own about 38.25% to 46.14% of the stock, and retail investors hold around 13.71% to 21.21%. Major institutional owners include RA Capital Management, L.P., Sands Capital Ventures, LLC, and Citadel Advisors Llc. A significant individual owner is Chione Ltd., holding 9.93% of the company's shares. Kristina Masson, a co-founder and Executive VP, also holds a notable percentage of shares.